Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Endpoints News, Fierce Biotech and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 100d ago.
Quick answers
Why is "Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial Bloomberg.com · 102d ago
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 102d ago
- Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 102d ago
- Roche drug sets new standard for KRAS-driven lung cancer STAT · 102d ago
- Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 102d ago
- Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 102d ago
Topics
Related trends
Apple confirms Beats x Pokémon collaboration with Pill speaker teaser
6 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Michael Douglas Recalls Turning to Drug Smuggling After Being Cut Off From Dad Kirk
4 news sources are covering this Entertainment story right now — PULSE is tracking how fast it spreads.
A preinvasive regulatory T cell axis for lung cancer interception
Recent scientific studies and medical reports examine a preinvasive regulatory T cell axis and immune fog for lung cancer interception.
Exercise Can Help Cancer Patients but Goes Uncovered
Recent coverage highlights new evidence regarding exercise safety for lung cancer patients undergoing chemotherapy.
Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
How a Promising Pancreatic Cancer Drug Loses Its Punch
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.